US biotech faces regulatory push as China licensing deals spark security concerns

A surge in licensing agreements between Chinese pharmaceutical firms and U.S. biotech companies has been noted, with nearly 100 deals announced since early 2025, prompting worry among investors and analysts.

Lawmakers are considering adding biotechnology to the list of sectors subject to heightened scrutiny for China-related investments, a move discussed at BIO’s annual meeting where panels examined the impact on business development and venture funding.

BIO chief executive John Crowley said the industry is caught between the benefits of cross‑border collaborations and the risks of potential congressional restrictions, highlighting the tough choices ahead for U.S. biotech.